2023 - Research.com Medicine in Japan Leader Award
His Internal medicine study frequently links to other fields, such as Proportional hazards model. His study in Malignant transformation extends to Pathology with its themes. Yasushi Yatabe combines Malignant transformation and Malignancy in his studies. His work often combines Malignancy and Atypia studies. His study deals with a combination of Atypia and Nuclear atypia. His Nuclear atypia study frequently links to related topics such as Immunohistochemistry. His work blends Immunohistochemistry and Pathology studies together. In his works, Yasushi Yatabe conducts interdisciplinary research on Cancer and Oncology. He integrates Oncology and Cancer in his studies.
As part of his studies on Internal medicine, Yasushi Yatabe often connects relevant areas like Chemotherapy. Yasushi Yatabe applies his multidisciplinary studies on Cancer and Epidermal growth factor receptor in his research. He integrates several fields in his works, including Pathology and Immunohistochemistry. Yasushi Yatabe conducted interdisciplinary study in his works that combined Immunohistochemistry and Pathology. In his works, he conducts interdisciplinary research on Genetics and Gene. His multidisciplinary approach integrates Gene and Genetics in his work. In his articles, he combines various disciplines, including Cancer research and Cancer. His research on Oncology often connects related areas such as Lung cancer. His research ties Oncology and Lung cancer together.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro.
Lancet Oncology (2010)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis;Elisabeth Brambilla;Andrew G. Nicholson;Yasushi Yatabe.
Journal of Thoracic Oncology (2015)
Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
Junichi Takamizawa;Hiroyuki Konishi;Kiyoshi Yanagisawa;Shuta Tomida.
Cancer Research (2004)
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita;Hirotaka Osada;Yoshio Tatematsu;Hideki Yamada.
Cancer Research (2005)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer Biological and Clinical Implications
Takayuki Kosaka;Yasushi Yatabe;Hideki Endoh;Hiroyuki Kuwano.
Cancer Research (2004)
Comprehensive genomic profiles of small cell lung cancer
Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun.
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi;Manabu Soda;Yoshihiro Yamashita;Toshihide Ueno.
The New England Journal of Medicine (2010)
Increased Expression of Cyclooxygenase 2 Occurs Frequently in Human Lung Cancers, Specifically in Adenocarcinomas
Toyoaki Hida;Yasushi Yatabe;Hiroyuki Achiwa;Hideki Muramatsu.
Cancer Research (1998)
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
Tetsuya Mitsudomi;Takayuki Kosaka;Hideki Endoh;Yoshitsugu Horio.
Journal of Clinical Oncology (2005)
If you think any of the details on this page are incorrect, let us know.